<p>Attention-Deficit/Hyperactivity Disorder (ADHD) is a complex neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning or development. As of 2025, the understanding of ADHD has evolved from a simplistic “chemical imbalance” model to a sophisticated neurobiological framework involving multiple neurotransmitter systems and neural circuits.</p>

<p>As the most prevalent neurodevelopmental disorder, ADHD affects approximately 7.2% to 11% of children globally. Longitudinal data indicate that ADHD persists into adulthood in approximately 4% to 5% of the general population. Furthermore, emerging studies suggest that up to 20% of adult cases may first manifest clinically significant symptoms during late adolescence, a phenomenon described as <strong>“late-onset” ADHD</strong>.</p>

<h3>Diagnosis and Symptoms</h3>
<p>The clinical diagnosis is based on DSM-5 criteria, requiring a persistent pattern of symptoms for at least six months, with an onset before age 12, occurring in more than one setting.</p>
<p>ADHD is phenotypically heterogeneous and is stratified into three primary clinical presentations:</p>
<ul>
    <li><strong>Predominantly Inattentive Presentation (ADHD-I):</strong> Difficulty sustaining attention, poor organizational skills, and a tendency to abandon tasks. Frequently underdiagnosed due to lack of overt disruption.</li>
    <li><strong>Predominantly Hyperactive/Impulsive Presentation (ADHD-H):</strong> Excessive motor activity, fidgeting, difficulty remaining seated, and impulsive decision-making. Most commonly identified in early childhood.</li>
    <li><strong>Combined Presentation (ADHD-C):</strong> The most prevalent form, meeting criteria for both domains.</li>
</ul>

<h3>Mechanism of Action: Pathophysiology</h3>
<p>The core neurobiological dysfunction involves dysregulation of catecholaminergic signalling—primarily <strong>dopamine (DA)</strong> and <strong>norepinephrine (NE)</strong>—within executive control networks.</p>

<div class="image-container">
    <img src="assets/images/adhd-catecholamine-signaling.png" alt="Catecholamine signalling in the Prefrontal Cortex">
    <p class="image-caption">Catecholamine signaling in the Prefrontal Cortex</p>
</div>

<h4>The Catecholamine Hypothesis</h4>
<ul>
    <li><strong>Dopamine (DA):</strong> Modulates D1 receptor activity to reduce background “noise,” enhancing focus on task-relevant stimuli. Insufficient DA in the prefrontal cortex (PFC) reduces the signal-to-noise ratio, impairing attention.</li>
    <li><strong>Norepinephrine (NE):</strong> Enhances "signal" strength via α2A receptors. Deficiency in the PFC impairs the ability to filter out irrelevant stimuli.</li>
</ul>

<h4>Emerging Neurotransmitter Systems</h4>
<ul>
    <li><strong>Glutamate:</strong> Dysregulation of metabotropic glutamate receptors (mGluRs) implies altered synaptic plasticity.</li>
    <li><strong>Serotonin (5-HT):</strong> Under investigation for addressing comorbid anxiety and mood instability.</li>
</ul>

<h3>Standard Care & Medications</h3>
<p>The standard of care is multimodal, combining psychoeducation, behavioural therapy, and pharmacotherapy.</p>

<h4>First-Line: CNS Stimulants</h4>
<p>Stimulants increase synaptic concentrations of DA and NE. They remain the most effective pharmacological intervention.</p>

<table style="width:100%; border-collapse: collapse; margin: 20px 0; font-size: 14px;">
  <thead>
    <tr style="background-color: #f6f8fa; text-align: left;">
      <th style="padding: 10px; border: 1px solid #d0d7de;">Class</th>
      <th style="padding: 10px; border: 1px solid #d0d7de;">Examples</th>
      <th style="padding: 10px; border: 1px solid #d0d7de;">Mechanism of Action</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="padding: 10px; border: 1px solid #d0d7de;"><strong>Methylphenidates (MPH)</strong></td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">Ritalin, Concerta, Quillivant XR</td>
      <td style="padding: 10px; border: 1px solid #d0d7de;"><strong>Reuptake Inhibitor:</strong> Blockade of DAT and NET, increasing neurotransmitter availability in the synaptic cleft.</td>
    </tr>
    <tr>
      <td style="padding: 10px; border: 1px solid #d0d7de;"><strong>Amphetamines (AMP)</strong></td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">Adderall, Vyvanse</td>
      <td style="padding: 10px; border: 1px solid #d0d7de;"><strong>Releaser & Inhibitor:</strong> Inhibits VMAT-2 to promote DA release; induces "reverse transport" via DAT; inhibits MAO activity.</td>
    </tr>
  </tbody>
</table>

<h4>Second-Line: Non-Stimulants</h4>
<p>Indicated when stimulants are poorly tolerated or contraindicated. These are critical for the ~20% of patients who are stimulant-refractory.</p>

<table style="width:100%; border-collapse: collapse; margin: 20px 0; font-size: 14px;">
  <thead>
    <tr style="background-color: #f6f8fa; text-align: left;">
      <th style="padding: 10px; border: 1px solid #d0d7de;">Medication</th>
      <th style="padding: 10px; border: 1px solid #d0d7de;">Mechanism</th>
      <th style="padding: 10px; border: 1px solid #d0d7de;">Clinical Notes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="padding: 10px; border: 1px solid #d0d7de;"><strong>Strattera</strong> (Atomoxetine)</td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">Selective NRI (SNRI)</td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">Increases DA/NE in PFC with minimal effect on reward pathways (low abuse potential). Delayed onset (2–6 weeks).</td>
    </tr>
    <tr>
      <td style="padding: 10px; border: 1px solid #d0d7de;"><strong>Intuniv</strong> (Guanfacine)</td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">Selective α2A Agonist</td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">Strengthens synaptic connectivity in PFC. Particularly effective for emotional dysregulation.</td>
    </tr>
    <tr>
      <td style="padding: 10px; border: 1px solid #d0d7de;"><strong>Qelbree</strong> (Viloxazine)</td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">Selective NET Inhibitor + 5-HT2B/2C activity</td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">Newer option (2021). Serotonergic activity may aid mood regulation. Rapid onset (1-2 weeks).</td>
    </tr>
  </tbody>
</table>

<h3>Novel Medications: The Next Generation</h3>
<p>Recent approvals have focused on optimizing delivery and broadening receptor targets.</p>
<ul>
    <li><strong>Azstarys (Prodrug Stimulant):</strong> A combination of immediate-release dexmethylphenidate and its prodrug serdexmethylphenidate. It provides a smooth effect from 30 minutes up to 13 hours.</li>
    <li><strong>Qelbree (Viloxazine XR):</strong> A Serotonin-Norepinephrine Modulating Agent (SNMA) that offers a non-stimulant option with a unique secondary mechanism targeting serotonin receptors.</li>
</ul>

<h3>Pipeline Watch: Clinical Trials (2025/2026)</h3>
<p>The pipeline focuses on multi-target agents and advanced delivery systems.</p>

<div class="image-container">
    <img src="assets/images/adhd-pipeline-2026.png" alt="ADHD Drug Development Pipeline 2026">
    <p class="image-caption">ADHD Drug Development Pipeline 2026</p>
</div>

<h4>Near Approval (NDA Submitted)</h4>
<ul>
    <li><strong>Centanafadine (Otsuka):</strong> A first-in-class <strong>SNDRI</strong> (Serotonin-Norepinephrine-Dopamine Reuptake Inhibitor). By inhibiting transporters for all three monoamines, it leverages focus-enhancing effects while harnessing mood-stabilizing properties. NDA submitted Nov 2025.</li>
    <li><strong>CTx-1301 (Cingulate):</strong> Uses triple-release technology to deliver medication in 3 distinct pulses, targeting 16-hour symptom control. PDUFA date: May 31, 2026.</li>
</ul>

<h4>Phase 3 Candidates</h4>
<table style="width:100%; border-collapse: collapse; margin: 20px 0; font-size: 14px;">
  <thead>
    <tr style="background-color: #f6f8fa; text-align: left;">
      <th style="padding: 10px; border: 1px solid #d0d7de;">Candidate</th>
      <th style="padding: 10px; border: 1px solid #d0d7de;">Mechanism</th>
      <th style="padding: 10px; border: 1px solid #d0d7de;">Significance</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="padding: 10px; border: 1px solid #d0d7de;"><strong>Solriamfetol</strong></td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">DNRI + TAAR1 Agonist</td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">Potential non-scheduled alternative with a cleaner cardiovascular profile than amphetamines.</td>
    </tr>
    <tr>
      <td style="padding: 10px; border: 1px solid #d0d7de;"><strong>Mazindol ER</strong></td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">Triple Reuptake + Orexin-2 Agonist</td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">Targets the "hypo-arousal" characteristic of inattention via the orexin wakefulness system.</td>
    </tr>
    <tr>
      <td style="padding: 10px; border: 1px solid #d0d7de;"><strong>Fasoracetam</strong></td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">mGluR Activator</td>
      <td style="padding: 10px; border: 1px solid #d0d7de;">Precision medicine approach for patients with specific mGluR gene mutations.</td>
    </tr>
  </tbody>
</table>

<h3>Conclusion</h3>
<p>The field of ADHD pharmacotherapy is undergoing a significant evolution. While the catecholamine hypothesis remains central, the development of multi-target agents like Centanafadine and the exploration of non-catecholaminergic pathways (e.g., glutamate and orexin systems) are creating a personalized treatment landscape.</p>

<h3>References</h3>
<ul class="references-list">
    <li><a href="https://my.clevelandclinic.org/health/treatments/11766-adhd-medication" target="_blank">Cleveland Clinic - ADHD Medication</a></li>
    <li><a href="https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-pipeline-insight" target="_blank">Attention Deficit Hyperactivity Disorder Pipeline Insight, 2025</a></li>
    <li><a href="https://www.ncbi.nlm.nih.gov/books/NBK482451/" target="_blank">StatPearls - Amphetamine</a></li>
    <li><a href="https://www.ncbi.nlm.nih.gov/books/NBK459124/" target="_blank">StatPearls - Clonidine</a></li>
    <li><a href="https://www.ncbi.nlm.nih.gov/books/NBK556103/" target="_blank">StatPearls - Methylphenidate</a></li>
    <li><a href="https://www.otsuka-us.com/news/otsuka-pharmaceutical-submits-new-drug-application-us-fda-centanafadine-treatment-adhd" target="_blank">Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults</a></li>
    <li><a href="https://www.cingulate.com/news-releases/news-release-details/fda-accepts-cingulates-new-drug-application-ctx-1301-attention" target="_blank">FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date</a></li>
    <li><a href="https://www.prnewswire.com/news-releases/nls-pharmaceutics-to-present-new-data-on-the-dual-efficacy-of-mazindol-er-in-fentanyl-reward-and-withdrawal-at-the-2025-ascp-annual-meeting-302461603.html" target="_blank">NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting</a></li>
    <li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9713849/" target="_blank">Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials</a></li>
</ul>
<br/>
